125469-91-2

Upstream product

• 125469-90-1 C₂₃H₂₉NO₄ 
• 100-39-0 benzyl bromide 
• 42550-72-1 methyl 2-benzyl-2-cyano-3-phenylpropionate 
• 125469-89-8 C₁₈H₂₁NO₂ 

Relevant academic research and scientific papers

THERAPEUTIC PEPTIDES

The present invention provides a peptide, peptidomimetic or amino acid derivative having a net positive charge of at least +2 and incorporating a disubstituted β amino acid, each of the substituting groups in the β amino acid, which may be the same or dif

Antimicrobial activity of small β-peptidomimetics based on the pharmacophore model of short cationic antimicrobial peptides

We have synthesized a series of small β-peptidomimetics (Mw 2,2-amino acid coupled to a C-terminal L-arginine amide residue. By varying the lipophilic side-chains of the β2,2-amino acids, we obtained a series of highly potent β-peptidomimetics with high enzymatic stability against α-chymotrypsin and a general low toxicity against human erythrocytes. The most potent β-peptidomimetics displayed minimal inhibitory concentrations of 2.1-7.2 μM against Staphylococcus aureus, methicillin resistant Staphylococcus aureus (MRSA), methicillin resistant Staphylococcus epidermidis (MRSE), and Escherichia coli. Small amphipathic β-peptidomimetics may be a promising class of antimicrobial agents by means of having a similar range of potency and selectivity as larger cationic antimicrobial peptides in addition to improved enzymatic stability and lower costs of production.